Skylands Capital LLC Purchases 28,600 Shares of Haemonetics Corporation (NYSE:HAE)

Skylands Capital LLC increased its position in shares of Haemonetics Corporation (NYSE:HAE - Free Report) by 105.2% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 55,775 shares of the medical instruments supplier's stock after buying an additional 28,600 shares during the quarter. Skylands Capital LLC owned about 0.11% of Haemonetics worth $3,545,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. TD Waterhouse Canada Inc. acquired a new position in shares of Haemonetics during the fourth quarter worth approximately $25,000. Covestor Ltd increased its stake in Haemonetics by 146.8% during the 4th quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier's stock valued at $58,000 after purchasing an additional 439 shares in the last quarter. Whittier Trust Co. acquired a new position in Haemonetics during the fourth quarter worth $62,000. Parkside Financial Bank & Trust lifted its stake in shares of Haemonetics by 25.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock valued at $92,000 after buying an additional 240 shares in the last quarter. Finally, AlphaQuest LLC grew its holdings in shares of Haemonetics by 36,520.0% during the fourth quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock valued at $143,000 after buying an additional 1,826 shares during the last quarter. Institutional investors own 99.67% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on HAE. Robert W. Baird started coverage on shares of Haemonetics in a report on Thursday, June 26th. They issued an "outperform" rating and a $87.00 target price on the stock. JMP Securities reissued a "market outperform" rating and issued a $100.00 price objective on shares of Haemonetics in a research note on Tuesday, May 20th. Raymond James Financial restated a "strong-buy" rating and issued a $105.00 target price (down previously from $115.00) on shares of Haemonetics in a report on Friday, May 9th. Baird R W upgraded Haemonetics to a "strong-buy" rating in a report on Wednesday, June 25th. Finally, Wall Street Zen lowered Haemonetics from a "buy" rating to a "hold" rating in a research report on Tuesday, May 13th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Haemonetics currently has an average rating of "Moderate Buy" and an average target price of $96.80.

Haemonetics Stock Performance

Haemonetics stock traded up $1.78 during mid-day trading on Tuesday, reaching $76.39. 724,389 shares of the company's stock were exchanged, compared to its average volume of 670,689. The business's fifty day simple moving average is $68.51 and its 200 day simple moving average is $68.08. The company has a quick ratio of 0.99, a current ratio of 1.62 and a debt-to-equity ratio of 1.12. Haemonetics Corporation has a one year low of $55.30 and a one year high of $94.99. The firm has a market capitalization of $3.67 billion, a PE ratio of 23.08, a P/E/G ratio of 1.21 and a beta of 0.39.

Haemonetics (NYSE:HAE - Get Free Report) last announced its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.22 by $0.02. The firm had revenue of $330.60 million during the quarter, compared to analyst estimates of $329.38 million. Haemonetics had a return on equity of 26.37% and a net margin of 12.32%. The business's revenue was down 3.5% compared to the same quarter last year. During the same period last year, the firm posted $0.90 EPS. On average, sell-side analysts expect that Haemonetics Corporation will post 4.55 earnings per share for the current year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.